LANSING, Mich., May 29, 2009 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that it has successfully issued its stock dividend. “The issuance of the dividend has been in the planning for some time and has been an important part of the Company’s plan for returning value to our shareholders. Just as important, we believe that the issuance has laid the groundwork for the Company’s long term future,” said CEO Kim K Thompson. “The input we have received from our shareholders throughout this process has been and continues to be overwhelmingly positive. We are also very excited about the progress in the laboratory and are very hopeful that the scientific team can maintain their tremendous forward momentum through the summer and fall and into 2010.”
Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.
For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com
The Kraig Biocraft Laboratories, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4817
This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.
Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO